I-Mab Biopharma Stock: Caution Warranted After Huge Surge (NASDAQ:IMAB)

Shares of immuno-oncology concern I-Mab (NASDAQ: IMAB ) have had a massive run in 2025 as enthusiasm has grown concerning its new lead asset, givastomig. The candidate in combo with chemo and Opdivo hit an ORR of 83% (10/12) acrossBret leads the investing group The Biotech Forum , in which he and his team offer a model portfolio with their favorite 12-20 high upside biotech stocks, live chat to discuss trade ideas, and weekly research and option trades. The group also provides market commentary and a portfo ...